Brimonidine Tartrate CAS No: 79570-19-7 Known for treating open-angle glaucoma, brimonidine tartrate is a safe and effective API for reducing pressure behind the eye. The medication allows better drainage of fluids to both relieve patient suffering and protect eyes from further damage. High-fluid pressure can cause anything from mild nerve damage to total blindness. However,[…]
Brimonidine Tartrate a Safe and Effective API for Reducing Pressure Behind the Eye
Drug Research & Development API Tags: glaucomalatanoprost Jul 09, 2018
Travoprost Remains a Reliable and Effective Glaucoma Treatment
Drug Research & Development API, OTC and Compounding Product, Prostaglandin Tags: glaucoma Sep 01, 2015
With a 5.6 billion dollar market worldwide for treating glaucoma, research and development of new treatments are both needed and inevitable. Travoprost, currently a safe and efficacious therapy, continues to be a reliable treatment for the onslaught of patients around the globe suffering from glaucoma. With no cure for this debilitating eye disease, glaucoma is[…]
Long Term Hypertension Leads to Glaucoma and Brinzolamide is a Viable Treatment Option
Anti-Hypertensive, Drug Research & Development API Tags: glaucomahypertensionintraocular pressure May 29, 2015
A new study published in the January 2015 Investigative Ophthalmology & Visual Science has shared alarming news regarding patients who suffer from long-term or chronic hypertension. Information gleaned from studies has revealed that people who are diagnosed with hypertension and who do not treat their condition are at a heightened risk for glaucoma. Ophthalmologists and[…]
Brimonidine Effectual for Soaring Rates of Glaucoma
Anti-Hypertensive, Drug Research & Development API Tags: glaucomaintraocular pressure May 14, 2015
By 2020 Glaucoma is predicted to affect over 80 million people worldwide as one of the leading causes of vision loss in adults. Approximately 10 percent of the patients diagnosed with Glaucoma will become bilaterally blind from this disease. Treatment to effectively and safely lower intraocular pressure is a must, with a growing rate of[…]
FDA Approves Dorzolamide for Lowering Intraocular Pressure
Drug Research & Development API, FDA Approved 2014, OTC and Compounding Product Tags: glaucomahypertensionintraocular pressure May 04, 2015
In late 2014 the FDA approved Dorzolamide Hydrochloride, to be used in conjunction with Timolol Maleate for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Known as the brand name eye drop Cosopt Opthamolic Solution, which is marketed by Lannett Company Inc., this solution has proven to be both[…]
Prostaglandin Analogue Latanoprost Indicated as Glaucoma Treatment
Drug Research & Development API, OTC and Compounding Product, Prostaglandin Tags: glaucomalatanoprostophthalmicprostaglandin Feb 05, 2015
As the most commonly prescribed treatment for glaucoma, Latanoprost has taken the pharmaceutical headlines by storm with the latest study data revelations. At the end of December 2014 The Lancet published remarkable study results indicating that the use of Latanoprost reduced the risk of glaucoma by over 50 percent when taken for two years’ time.[…]
Dorzolamide Hydrochloride Successfully Treats Open Angle Glaucoma
Bulk Active Ingredient, Drug Research & Development API, OTC and Compounding Product, TEVA API Tags: glaucomahypertensionintraocular pressure Mar 19, 2012
Dorzolamide Hydrochloride is an eye drop indicated for the treatment of ocular hypertension and open angle glaucoma. Also known by the trade names Trusopt and Cosopt, Dorzolamide Hydrochloride works by inhibiting the isoenzyme carbonic anhydrase, also termed CA-II. This inhibition helps to decrease the amount of fluid made within the eye, thus decreasing pressure in the affected[…]
